Cargando…

Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab

Lipoprotein(a) (Lp[a]) is the most common genetically inherited risk factor for cardiovascular disease. Many aspects of Lp(a) metabolism remain unknown. We assessed the uptake of fluorescent Lp(a) in primary human lymphocytes as well as Lp(a) hepatic capture in a mouse model in which endogenous hepa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chemello, Kévin, Beeské, Sandra, Trang Tran, Thi Thu, Blanchard, Valentin, Villard, Elise F., Poirier, Bruno, Le Bail, Jean-Christophe, Dargazanli, Gihad, Ho-Van-Guimbal, Sophie, Boulay, Denis, Bergis, Olivier, Pruniaux, Marie-Pierre, Croyal, Mikaël, Janiak, Philip, Guillot, Etienne, Lambert, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	PRECLINICAL RESEARCH
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315184/ https://www.ncbi.nlm.nih.gov/pubmed/32613143 http://dx.doi.org/10.1016/j.jacbts.2020.03.008

Ejemplares similares

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab
por: Villard, Elise F., et al.
Publicado: (2016)

High Glucose Activates YAP Signaling to Promote Vascular Inflammation
por: Ortillon, Jeremy, et al.
Publicado: (2021)

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
por: McDonagh, Marian, et al.
Publicado: (2016)

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
por: Reyes-Soffer, Gissette, et al.
Publicado: (2017)

Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats
por: Huang, Hui-Chun, et al.
Publicado: (2022)

Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer
por: Bhardwaj, Anjana, et al.
Publicado: (2021)

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
por: Choi, Hye Duck, et al.
Publicado: (2023)

A G-protein-biased S1P(1) agonist, SAR247799, improved LVH and diastolic function in a rat model of metabolic syndrome
por: Evaristi, Maria Francesca, et al.
Publicado: (2022)

Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models
por: Trendowski, Matthew, et al.
Publicado: (2015)

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy
por: Koren, Michael J., et al.
Publicado: (2015)

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
por: Hopkins, Paul N., et al.
Publicado: (2015)

Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo
por: Myers, Tashanna, et al.
Publicado: (2008)

In Vivo Imaging of Venous Thrombus and Pulmonary Embolism Using Novel Murine Venous Thromboembolism Model
por: Okano, Mitsumasa, et al.
Publicado: (2020)

FYCO1 Regulates Cardiomyocyte Autophagy and Prevents Heart Failure Due to Pressure Overload In Vivo
por: Kuhn, Christian, et al.
Publicado: (2021)

In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
por: Yu, Yi, et al.
Publicado: (2017)

Ad-VT enhances the sensitivity of chemotherapy-resistant lung adenocarcinoma cells to gemcitabine and paclitaxel in vitro and in vivo
por: Song, Gaojie, et al.
Publicado: (2022)

In Vivo Imaging of Tissue-Engineered Grafts Within Pulmonary Artery of a Growing Large Animal Model
por: Bates, Novella M., et al.
Publicado: (2022)

The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents
por: Griebel, Guy, et al.
Publicado: (2018)

Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration
por: Trendowski, Matthew, et al.
Publicado: (2015)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro
por: Lou, Rui, et al.
Publicado: (2019)

Osthole inhibits the progression of human gallbladder cancer cells through JAK/STAT3 signal pathway both in vitro and in vivo
por: Le Zou, Tian, et al.
Publicado: (2019)

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
por: Bergman, Andries M., et al.
Publicado: (2010)

CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo
por: Koch, Manuel, et al.
Publicado: (2010)

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
por: Gelbert, Lawrence M., et al.
Publicado: (2014)

A better experimental method to detect the sensitivity of cancer cells to anticancer drugs after adenovirus-mediated introduction of two kinds of p53 in vivo
por: Wang, Hui, et al.
Publicado: (2015)

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
por: Colhoun, Helen M., et al.
Publicado: (2016)

Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice
por: Kapuvári, Bence, et al.
Publicado: (2016)

Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer
por: van Gelder, Michel, et al.
Publicado: (2016)

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
por: Wander, Seth A., et al.
Publicado: (2013)

In Vivo Reactive Oxygen Species Detection With a Novel Positron Emission Tomography Tracer, (18)F-DHMT, Allows for Early Detection of Anthracycline-Induced Cardiotoxicity in Rodents
por: Boutagy, Nabil E., et al.
Publicado: (2018)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
por: Choi, Joshua, et al.
Publicado: (2017)

Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study
por: Banach, Maciej, et al.
Publicado: (2023)

A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo
por: Suchowerska, Alexandra K., et al.
Publicado: (2022)

PCSK9 and the nervous system: a no-brainer?
por: Jaafar, Ali K., et al.
Publicado: (2023)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
por: Schreckenberg, Rolf, et al.
Publicado: (2022)

Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes
por: Ramanathan, Aarti, et al.
Publicado: (2016)

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
por: Jukema, J. Wouter, et al.
Publicado: (2019)

PCSK9 Imperceptibly Affects Chemokine Receptor Expression In Vitro and In Vivo
por: Sundararaman, Sai Sahana, et al.
Publicado: (2021)

PCSK9 is not secreted from mature differentiated intestinal cells
por: Moreau, François, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_egs1avrtjbubblnkbogv15sr51